Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 10;332(22):1941-1943.
doi: 10.1001/jama.2024.20429.

HLA-DRB1*01:03 and Severe Ulcerative Colitis

Marie Vibeke Vestergaard  1 , Anne Krogh Nøhr  1 , Kristine Højgaard Allin  1   2 , Henrik Krarup  3   4 , Lone Larsen  1   2 , Aleksejs Sazonovs  1 , Tine Jess  1   2
Affiliations

HLA-DRB1*01:03 and Severe Ulcerative Colitis

Marie Vibeke Vestergaard et al. JAMA. .
No abstract available

Plain language summary

This Danish nationwide genome-wide association study aims to identify biomarkers of severe vs less severe ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Larsen reported receiving personal fees from Takeda and Tillotts outside this study. Dr Jess reported receiving personal fees from Ferring and Pfizer outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. HLA-DRB1*01:03 Genotype Associated With Severe Ulcerative Colitis
Figure 2.
Figure 2.. HLA-DRB1*01:03 Genotype and Time to First Event of Different Severity Entities
A, Time from date of diagnosis to first ulcerative colitis–related hospitalization exceeding 2 days split by genotype of HLA-DRB1*01:03. B, Time from date of diagnosis to first major ulcerative colitis–related operation split by genotype of HLA-DRB1*01:03. C, Time from date of diagnosis to first treatment with systemic corticosteroids (500 mg) split by genotype of HLA-DRB1*01:03. Shaded areas correspond to the 95% CIs.
See this image and copyright information in PMC

References

    1. Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571-584. doi:10.1016/S0140-6736(23)00966-2 - DOI - PubMed
    1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. doi:10.1016/S0140-6736(16)32126-2 - DOI - PMC - PubMed
    1. Agrawal M, Christensen HS, Bøgsted M, Colombel JF, Jess T, Allin KH. The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. Gastroenterology. 2022;163(6):1547-1554.e5. doi:10.1053/j.gastro.2022.07.062 - DOI - PMC - PubMed
    1. Larsen L, Karachalia Sandri A, Fallingborg J, et al. . Has the incidence of inflammatory bowel disease peaked? evidence from the population-based NorDIBD Cohort 1978-2020. Am J Gastroenterol. 2023;118(3):501-510. doi:10.14309/ajg.0000000000002187 - DOI - PubMed
    1. Goyette P, Boucher G, Mallon D, et al. ; International Inflammatory Bowel Disease Genetics Consortium; Australia and New Zealand IBDGC; Belgium IBD Genetics Consortium; Italian Group for IBD Genetic Consortium; NIDDK Inflammatory Bowel Disease Genetics Consortium; United Kingdom IBDGC; Wellcome Trust Case Control Consortium; Quebec IBD Genetics Consortium . High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47(2):172-179. doi:10.1038/ng.3176 - DOI - PMC - PubMed